NASDAQ:ATTO Attovia Therapeutics (ATTO) Stock Price, News & Analysis $20.62 -0.18 (-0.87%) Closing price 08/24/2026 04:00 PM EasternExtended Trading$20.64 +0.02 (+0.10%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisChartInsider TradesNews and TrendsOwnershipSEC Filings About Attovia Therapeutics Stock (NASDAQ:ATTO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Attovia Therapeutics alerts:Sign Up Key Stats Today's Range$19.74▼$20.9650-Day Range N/A52-Week Range$16.15▼$24.32Volume80,992 shsAverage Volume693,925 shsMarket Capitalization$887.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs. Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. Its pipeline is centered on potential treatments for conditions involving dysregulated immune responses, although many of its programs remain in development and are subject to clinical and regulatory evaluation. As a development-stage biotechnology company, Attovia’s activities primarily involve research, preclinical studies, clinical trials and the advancement of its proprietary therapeutic pipeline. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on developing innovative treatments for inflammatory diseases.AI Generated. May Contain Errors. Read More Receive ATTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Attovia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATTO Stock News HeadlinesAttovia Therapeutics (NASDAQ:ATTO) Stock Price Up 7.5% After Insider Buying ActivityAugust 19, 2026 | americanbankingnews.comMeet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the SourceAugust 17, 2026 | 247wallst.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 25 at 1:00 AM | Porter & Company (Ad)Colin Walsh Acquires 85,000 Shares of Attovia Therapeutics (NASDAQ:ATTO) StockAugust 16, 2026 | americanbankingnews.comInsider Buying: Attovia Therapeutics (NASDAQ:ATTO) Director Acquires $1,785,000.00 in StockAugust 15, 2026 | insidertrades.comColin Walsh Sells 105,807 Shares of Attovia Therapeutics (NASDAQ:ATTO) StockAugust 14, 2026 | insidertrades.comRedmile Group, Llc Buys 200,000 Shares of Attovia Therapeutics (NASDAQ:ATTO) StockAugust 11, 2026 | insidertrades.comAttovia Therapeutics (NASDAQ:ATTO) Major Shareholder Buys 400,000 SharesAugust 8, 2026 | insidertrades.comSee More Headlines ATTO Stock Analysis - Frequently Asked Questions How have ATTO shares performed this year? Attovia Therapeutics' stock was trading at $21.90 on August 5, 2026. Since then, ATTO stock has decreased by 5.8% and is now trading at $20.62. When did Attovia Therapeutics IPO? Attovia Therapeutics (ATTO) raised $272 million in an initial public offering (IPO) on Wednesday, August 5th 2026. The company issued 17,000,000 shares at $15.00-$17.00 per share. When does Attovia Therapeutics' quiet period expire? Attovia Therapeutics's quiet period expires on Monday, September 14th. Attovia Therapeutics had issued 17,000,000 shares in its initial public offering on August 5th. The total size of the offering was $289,000,000 based on an initial share price of $17.00. During Attovia Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. Who are Attovia Therapeutics' major shareholders? Attovia Therapeutics' top institutional investors include BlackRock Inc.. Insiders that own company stock include Life Sciences Xi LP Frazier, Global Strategic Fund I Venbio, Goldman Sachs Group Inc, Colin Walsh and Redmile Group, Llc. View institutional ownership trends. How do I buy shares of Attovia Therapeutics? Shares of ATTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ATTO CIK2058707 Webwww.attovia.com Phone(510) 399-5001FaxN/AEmployees44Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares43,030,000Free FloatN/AMarket Cap$887.28 million OptionableN/A BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ATTO) was last updated on 8/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Attovia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Attovia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATTO Stock Alerts